Nice close! Good financials, and final release of obliques should win a lot of new business. Has run hard on minimal news before. Will consider selling when it's back to .95 or higher.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
AXN Rising demand, China's 'tech war' bans leaves this germanium explorer with significant investment potential
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025